Sunaina Pai Nayak
About Sunaina Pai Nayak
Sunaina Pai Nayak is a Senior Scientist specializing in small molecule drug discovery, particularly in oncology and tumor metabolism. She has extensive experience in the pharmaceutical industry, having worked at several organizations including Ribon Therapeutics and FORMA Therapeutics.
Work at Accent Therapeutics
Sunaina Pai Nayak currently holds the position of Senior Scientist at Accent Therapeutics, Inc., a role she has occupied since 2020. Her work focuses on advancing research in the field of oncology, particularly in small molecule drug discovery. Accent Therapeutics is known for its innovative approaches to cancer treatment, and Nayak contributes her expertise to the development of new therapeutic strategies.
Previous Experience at Ribon Therapeutics
Before joining Accent Therapeutics, Nayak worked as a Scientist at Ribon Therapeutics from 2019 to 2020. During her tenure in Cambridge, Massachusetts, she was involved in research initiatives aimed at developing novel therapies for cancer treatment. Her role contributed to the company's mission of targeting RNA biology to create effective cancer therapies.
Experience at FORMA Therapeutics, Inc.
Nayak's experience at FORMA Therapeutics, Inc. spans several years, where she served as a Principal Research Associate from 2017 to 2020 and previously as a Research Associate in Biology from 2011 to 2015. In these roles, she focused on small molecule drug discovery, contributing to projects that addressed oncology and tumor metabolism. Her work at FORMA helped advance the understanding of protein homeostasis in cancer.
Educational Background in Pharmaceutical Sciences
Sunaina Pai Nayak earned her Master of Science in Pharmaceutical Sciences from Northeastern University, where she studied from 2006 to 2008. Her academic background provided her with a solid foundation in drug development and therapeutic strategies, which she has applied throughout her career in the pharmaceutical industry.
Research Contributions and Thesis Work
Nayak authored a thesis titled 'Invitro Evaluations of Multifunctional Polymeric Nanoparticles for Simultaneous EGFR siRNA and Paclitaxel Delivery to Pancreatic Cancer cells.' This research highlights her focus on innovative drug delivery systems and her commitment to addressing challenges in cancer treatment through advanced therapeutic approaches.